Introduction to Early Consideration on In Vivo Diagnostic Drug Development
According to the Early Consideration document issued by the Pharmaceuticals and Medical Devices Agency (PMDA) on March 12, 2026, PMDA outlined key considerations for the clinical development of in vivo diagnostic drugs, including diagnostic radiopharmaceuticals.
The document aims to provide a common scientific framework for clinical development strategies, especially as global clinical trials and the use of overseas clinical data have become increasingly common in Japan. PMDA noted that existing guidance for diagnostic radiopharmaceuticals does not fully address newer global development approaches, leading to frequent regulatory discussions during development.
Importance of Clinical Utility and Diagnostic Accuracy
PMDA clarified that the clinical utility of in vivo diagnostic drugs should be demonstrated from two perspectives:
The guidance emphasizes that sponsors should clearly define the intended clinical use of the product, such as disease detection, staging, lesion localization, or surgical guidance, and design studies accordingly.
Encouragement of Global Clinical Development Strategies
To accelerate patient access to innovative diagnostic drugs in Japan, PMDA encourages participation in global clinical trials whenever ethnic factors are unlikely to significantly impact diagnostic performance.
For products such as diagnostic radiopharmaceuticals and imaging agents, PMDA states that sponsors may rely primarily on overseas clinical data if:
This approach could significantly reduce development burden and support more efficient simultaneous global development programs.
PMDA also recommends involving Japanese image readers in the evaluation of overseas imaging data and developing training materials for image interpretation to support consistent diagnostic performance in Japan.
Flexibility in Confirmatory Trial Design
The document explains that comparative studies against existing diagnostic methods are generally recommended when comparable diagnostic approaches already exist. However, PMDA acknowledges that comparative trials may not always be feasible. In such cases, single-arm studies using predefined diagnostic performance thresholds may be acceptable if adequately justified using historical data, literature, and prior clinical evidence.
This clarification may provide additional flexibility for sponsors developing innovative imaging agents or products targeting rare diseases.
Recommendations for Diagnostic Performance Endpoints
PMDA recommends using diagnostic accuracy against a Standard of Truth (SOT) as the primary endpoint in confirmatory studies. Sensitivity and specificity are generally expected to be primary evaluation metrics.
However, the guidance also recognizes that endpoint selection should depend on the intended clinical use. For example:
PMDA advises sponsors to consult with the agency when alternative endpoint strategies are considered.
Recommendations for Imaging Evaluation Procedures
To improve objectivity and reproducibility in imaging assessments, PMDA recommends that image evaluations be conducted by at least two independent readers, preferably three or more.
The guidance also emphasizes the importance of:
These recommendations are intended to improve consistency and reliability of imaging-based evaluations.
Clinical Benefit and Explanation of Clinical Significance
PMDA states that sponsors should explain the clinical significance of diagnostic drugs based on the clinical benefits provided to patients, such as:
Importantly, PMDA notes that additional interventional clinical outcome studies may not always be necessary if sufficient medical consensus already exists in clinical guidelines or literature regarding the clinical usefulness of the diagnostic information.
However, if the clinical value of acting on the diagnostic result is not yet established, sponsors may need to demonstrate improved clinical outcomes through dedicated clinical studies.
Conclusion
This Early Consideration provides Japan’s first comprehensive regulatory perspective on the clinical development of in vivo diagnostic drugs, including diagnostic radiopharmaceuticals and imaging agents. By clarifying expectations for global clinical development, overseas data utilization, confirmatory study design, and imaging evaluation, PMDA is promoting more efficient and globally harmonized development pathways while maintaining scientific rigor.
Reference